Hepatitis B flare: the good, the bad and the ugly

ABSTRACT Introduction Hepatitis B flare, defined as an event of abrupt ALT elevation to >5x ULN, is a frequent episode during the natural course or during/after antiviral therapy of chronic HBV infection, in both HBeAg-positive and HBeAg-negative patients with chronic hepatitis B or liver cirrhosis. Areas covered The definition, pathogenesis, clinical presentation, and management of hepatitis B flares in the published literature were reviewed. Hepatitis B flares have been considered as a result of the robust immune response of the patient to an upsurging HBV/HBV-antigen(s). ‘Host-dominating flares,’ reflect effective immune response, may resolve with ALT normalization and decline of HBV/ antigen(s). Contradictorily, ‘virus-dominating flares,’ reflect ineffective immune response, are usually followed by persistent/intermittent hepatitis and may even develop hepatic decompensation/failure. Expert opinion Not all hepatitis B flares require antiviral therapy, and close observation with combined HBsAg/ALT kinetics along the ascending ALT during hepatitis flare may differentiate hepatitis flares for an appropriate treatment/retreatment decision. More studies are needed to verify this proposal. Further immunologic studies using multiple samples during hepatitis B flare are important to clarify the precise underlying mechanisms as the basis for further improvement in the management of hepatitis flare.

[1]  Y. Liaw,et al.  Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection , 2022, Current Hepatology Reports.

[2]  Y. Liaw,et al.  The role of off-therapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Y. Liaw,et al.  Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  Y. Liaw,et al.  Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation” , 2022, The Kaohsiung journal of medical sciences.

[5]  Y. Liaw,et al.  Current Trend in Antiviral Therapy for Chronic Hepatitis B , 2022, Viruses.

[6]  Y. Liaw,et al.  Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses , 2022, International journal of molecular sciences.

[7]  Y. Liaw,et al.  Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Y. Liaw,et al.  Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. , 2021, The Journal of antimicrobial chemotherapy.

[9]  V. Sundararajan,et al.  Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis , 2021, Gut.

[10]  V. Wong,et al.  Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. , 2021, The Journal of infectious diseases.

[11]  T. Berg,et al.  The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy. , 2021, Journal of hepatology.

[12]  Y. Liaw Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg‐Negative Chronic Hepatitis B: To Retreat or Not to Retreat , 2020, Hepatology.

[13]  R. Chung,et al.  Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. , 2020, Journal of hepatology.

[14]  A. Lok,et al.  Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. , 2020, The lancet. Gastroenterology & hepatology.

[15]  Y. Liaw,et al.  Re‐treatment for severe hepatitis flare in HBeAg‐negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics , 2019, Journal of viral hepatitis.

[16]  William M. Lee,et al.  Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Y. Liaw Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift , 2019, Hepatology International.

[18]  Y. Liaw Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection , 2019, Nature Reviews Gastroenterology & Hepatology.

[19]  Guohong Deng,et al.  TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. , 2019, Journal of hepatology.

[20]  Y. Liaw,et al.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.

[21]  Y. Liaw,et al.  HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients. , 2018, Gastroenterology.

[22]  Y. Liaw,et al.  Great and rapid HBsAg decline in patients with on‐treatment hepatitis flare in early phase of potent antiviral therapy , 2018, Journal of viral hepatitis.

[23]  Y. Liaw,et al.  Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. , 2014, Journal of hepatology.

[24]  S. Locarnini,et al.  Anti‐viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post‐partum flare , 2014, Alimentary pharmacology & therapeutics.

[25]  A. Lok,et al.  Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.

[26]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[27]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[28]  Y. Liaw,et al.  Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  M. Brunetto A new role for an old marker, HBsAg. , 2010, Journal of hepatology.

[30]  J. Stockman,et al.  Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B , 2010 .

[31]  S. Lewin,et al.  Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. , 2009, The Journal of infectious diseases.

[32]  R. D. de Man,et al.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.

[33]  Y. Liaw,et al.  No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations , 2004, Antiviral therapy.

[34]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[35]  Y. Liaw,et al.  The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B , 2003 .

[36]  Y. Liaw,et al.  The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. , 2003, Journal of hepatology.

[37]  M. Brunetto,et al.  Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. , 2003, Journal of hepatology.

[38]  C. Wai,et al.  Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B , 2002, Gut.

[39]  R. Perrillo Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[40]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .

[41]  Y. Liaw,et al.  Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. , 2008, Liver.

[42]  C. Chan,et al.  Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. , 1990, Gastroenterology.

[43]  A. Lok,et al.  Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. , 1990, Journal of hepatology.

[44]  C. Chu,et al.  Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody‐positive patients , 1987, Hepatology.

[45]  C. Chu,et al.  Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis , 1987, Hepatology.

[46]  C. Chu,et al.  Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. , 2008, Liver.

[47]  C. Chu,et al.  Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. , 1985, Gastroenterology.

[48]  C. Chu,et al.  Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. , 1985, Journal of hepatology.

[49]  C. Chu,et al.  Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. , 1983, Gastroenterology.

[50]  H. Popper,et al.  The vocabulary of chronic hepatitis. , 1971, The New England journal of medicine.